MedTrace Logo

Precision Medicine in Chinese Patients With Young Onset Diabetes

NCT04049149 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 884

Last updated 2022-07-20

No results posted yet for this study

Summary

Patients with young onset diabetes (YOD) are one of the most challenging groups of patients due to their long disease duration, complex causes, delayed interventions, psychosocial stress, poor adherence and frequent default. The investigator's previous studies indicate that provision of biogenetic information improved satisfaction, reduced ambiguity and improved self-efficacy in patients with T2D. Provision of personalized information using the web-based Joint Asia Diabetes Evaluation (JADE) Technology with risk stratification and decision support empowers better self care and medical intervention with improved control of risk factors. To further improve the precision of diagnosis for individualizing care, the use of CP, GADA, genetic risk scores (GRS) or rare genetic variants of maturity onset of diabetes (MODY) can help doctors select the most appropriate therapy in a timely manner. While patients with low CP, GADA and high GRS will benefit from early insulin therapy, some MODY variants are associated with good response to insulin-releasing oral drugs (e.g. sulphonylurea) which may spare the use of insulin with reduced patient distress and over-insulinization. By contrast, patients with high CP often due to obesity-associated insulin resistance should undergo intensive lifestyle modification and use of drugs with weight-reducing or neutral effects to avoid weight gain due to excessive dose of insulin.

Conditions

Interventions

OTHER

Biogenetic explanation and endocrinologist intensive managment

* JADE report and JADE APP * Biogenetic explanation * First-year intensive management by endocrinologists * Follow up by their usual care doctors for continue treatment regimen maintenance. * Yearly DM nurses follow up for blood taking and questionnaires

OTHER

Usual care management

* JADE report and JADE APP * Attend their usual care clinic for ongoing treatment * Yearly DM nurses follow up for blood taking and questionnaires

Sponsors & Collaborators

  • Chinese University of Hong Kong

    lead OTHER

Principal Investigators

  • Juliana Chan, MD · Chinese University of Hong Kong

Study Design

Allocation
RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-14
Primary Completion
2024-12-31
Completion
2024-12-31

Countries

  • Hong Kong

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04049149 on ClinicalTrials.gov